ARVN - Arvinas discloses five additional preclinical programs

Arvinas ([[ARVN]] +1.6%) has announced platform updates and disclosed five additional programs from its preclinical pipeline, utilizing its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.Apart from preclinical programs, PROTAC protein degraders is in two clinical-stage programs - ARV-110 for metastatic castrate-resistant prostate cancer; and ARV-471 for locally advanced or metastatic ER+/HER2- breast cancer. Updated data from both the programs is expected during the quarter.Newly announced programs include:Address the scaffolding function of B-cell lymphoma 6 protein (BCL6) a transcriptional repressor implicated in B cell lymphomas and facilitates B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage response. Arvinas anticipates filing an IND for this program in 2022.Pan-KRAS mutant and mutant-specific KRAS degraders,

For further details see:

Arvinas discloses five additional preclinical programs